同时与延迟的逆侧乳腺对称化的安全性:系统性审查和元分析
Carol Y Wang1, Keisha E Montalmant1, Travis Peng1
1Division of Plastic and Reconstructive Surgery, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
概括
在乳房重建中同时进行乳房对称是与延迟方法一样安全,并发症和重新手术率相似. 这一发现支持了共享决策的同时程序的安全性.
科学领域:
- 整形外科 整形外科 整形外科
- 重建性手术是一种重建性手术.
- 在瘤学瘤学.
背景情况:
- 经过单边乳房重建后,反侧乳房对称化通常是必要的.
- 对称化的最佳时间 (同时与延迟) 被争论.
- 这项研究比较了同步和延迟的逆侧对称化的安全结果.
研究的目的:
- 为了比较同步与延迟的逆侧乳房对称化的安全结果.
- 为外科医生和患者之间共享决策提供数据.
主要方法:
- 按照PRISMA指南进行系统审查.
- 搜索了PubMed,Embase和Scopus的相关研究.
- 对并发症和重新手术率的元分析.
主要成果:
- 包括11项研究 (1263名患者);697项同时进行,566项延迟进行.
- 综合并发症率 (同时发生):17%;重复手术率 (同时发生):28%.
- 同时和延迟组之间的并发症或重新手术没有显著差异 (P > 0.05).
结论:
- 同时进行乳房对称证明了与延迟对称相比的安全性.
- 支持乳房重建同时进行手术的安全性.
- 告知外科医生-患者关于对称的时间的决策.
更多相关视频
09:51The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
2.6K
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.5K
相关概念视频
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...